ArticleScientific reports2026
Dissecting temporal regulation of the TLR4-IL-6 axis using systematic targeted inhibition.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Acute systemic inflammatory disorders, such as cytokine release syndrome or sepsis, remain among the leading causes of mortality. To better understand early inflammatory dynamics, we developed an ex vivo model using human peripheral blood mononuclear cells to study IL-6 release kinetics via the Toll-like receptor 4 pathway. A consistent kinetic profile was observed and described with a mixed-effects model. To further dissect the signaling hierarchy, we investigated the response dynamics of multiple inhibitors targeting the various stages of signaling at different timepoints. The results suggest individual differences with common patterns of IL-6 kinetics and indicate that sustained IL-6 release requires continuous upstream signaling. Furthermore, important feedback mechanisms were identified, with NF-κB and p38 emerging as critical regulators when compared with other members. The translational relevance of our model was further supported and validated by the use of clinically applied drugs, which demonstrated consistent effects with their known clinical activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.